Analyst Rating Update on Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S (NASDAQ:ASND) : The consensus on Ascendis Pharma A/S (NASDAQ:ASND) based on 3 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

Ascendis Pharma A/S (NASDAQ:ASND) : 2 investment research analysts covering Ascendis Pharma A/S (NASDAQ:ASND) have an average price target of $27 for the near short term. The highest target price given by the Brokerage Firm to the stock is $30 and the lowest target is $24 for the short term. Analysts expect the variance to be within $4.24 of the average price.

For this week, the average consensus of the company shares are rated as a Strong Buy.

Ascendis Pharma A/S (NASDAQ:ASND): stock turned positive on Tuesday. Though the stock opened at $13.07, the bulls momentum made the stock top out at $13.5 level for the day. The stock recorded a low of $12.5 and closed the trading day at $13.39, in the green by 3.56%. The total traded volume for the day was 1,087,939. The stock had closed at $12.93 in the previous days trading.

Ascendis Pharma A/S is a clinical stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its lead product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Insulin for the treatment of diabetes, TransCon Peptide for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.